Dashboard
Manage Tickers

EXEL EXELIXIS, INC.

Nasdaq exelixis.com


$ 36.17 $ -0.05 (-0.14 %)    

Wednesday, 22-Oct-2025 18:20:27 EDT
CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ $ 605.50 $ -5.89 (-0.96 %)
DIA $ 465.14 $ -3.44 (-0.73 %)
SPY $ 667.72 $ -3.49 (-0.52 %)
TLT $ 92.20 $ 0.06 (0.07 %)
GLD $ 377.31 $ 0.04 (0.01 %)
$ 36.08
$ 35.96
$ 36.17 x 274
$ 36.72 x 800
$ 35.44 - $ 36.45
$ 27.86 - $ 49.62
3,035,318
na
9.71B
$ 0.68
$ 16.13
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 07-28-2025 07-04-2025 10-Q
2 05-13-2025 04-04-2025 10-Q
3 02-11-2025 01-03-2025 10-K
4 10-29-2024 09-27-2024 10-Q
5 08-06-2024 06-28-2024 10-Q
6 04-30-2024 03-29-2024 10-Q
7 02-06-2024 12-29-2023 10-K
8 11-01-2023 09-29-2023 10-Q
9 08-01-2023 06-30-2023 10-Q
10 05-09-2023 03-31-2023 10-Q
11 02-07-2023 12-30-2022 10-K
12 11-01-2022 09-30-2022 10-Q
13 08-09-2022 07-01-2022 10-Q
14 05-10-2022 04-01-2022 10-Q
15 02-18-2022 12-31-2021 10-K
16 11-02-2021 10-01-2021 10-Q
17 08-05-2021 07-02-2021 10-Q
18 05-06-2021 04-02-2021 10-Q
19 02-11-2021 01-01-2021 10-K
20 11-05-2020 10-02-2020 10-Q
21 08-06-2020 07-03-2020 10-Q
22 05-05-2020 04-03-2020 10-Q
23 02-25-2020 01-03-2020 10-K
24 10-30-2019 09-27-2019 10-Q
25 07-31-2019 06-28-2019 10-Q
26 05-01-2019 03-29-2019 10-Q
27 02-22-2019 12-28-2018 10-K
28 11-01-2018 09-28-2018 10-Q
29 08-01-2018 06-29-2018 10-Q
30 05-02-2018 03-30-2018 10-Q
31 02-26-2018 12-29-2017 10-K
32 11-01-2017 09-29-2017 10-Q
33 08-02-2017 06-30-2017 10-Q
34 05-01-2017 03-31-2017 10-Q
35 02-27-2017 12-30-2016 10-K
36 11-03-2016 09-30-2016 10-Q
37 08-03-2016 07-01-2016 10-Q
38 05-04-2016 04-01-2016 10-Q
39 02-29-2016 01-01-2016 10-K
40 11-10-2015 10-02-2015 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

morgan-stanley-maintains-overweight-on-exelixis-lowers-price-target-to-44
Morgan Stanley Maintains Overweight on Exe...
10/21/2025 17:11:01

Morgan Stanley analyst Sean Laaman maintains Exelixis (NASDAQ:EXEL) with a Overweight and lowers the price target from $50 t...

rbc-capital-reiterates-sector-perform-on-exelixis-maintains-45-price-target
RBC Capital Reiterates Sector Perform on E...
10/21/2025 14:37:17

RBC Capital analyst Leonid Timashev reiterates Exelixis (NASDAQ:EXEL) with a Sector Perform and maintains $45 price target.

wells-fargo-maintains-equal-weight-on-exelixis-lowers-price-target-to-30
Wells Fargo Maintains Equal-Weight on Exel...
10/21/2025 13:07:35

Wells Fargo analyst Derek Archila maintains Exelixis (NASDAQ:EXEL) with a Equal-Weight and lowers the price target from $36 ...

this-nextracker-analyst-turns-bullish-here-are-top-5-upgrades-for-tuesday
This Nextracker Analyst Turns Bullish; Her...
10/21/2025 12:27:16

leerink-partners-upgrades-exelixis-to-outperform-announces-48-price-target
Leerink Partners Upgrades Exelixis to Outp...
10/21/2025 10:27:38

Leerink Partners analyst Christopher Liu upgrades Exelixis (NASDAQ:EXEL) from Market Perform to Outperform and announces $48...

exelixis-stock-falls-after-phase-3-colorectal-cancer-trial-shows-mixed-results
Exelixis Stock Falls After Phase 3 Colorec...
10/20/2025 14:48:53

Exelixis stock dips after Phase 3 data show modest survival gains from zanzalintinib and Tecentriq combo in colorectal cancer p...

olema-pharmaceuticals-exelixis-genmab-and-other-big-stocks-moving-lower-in-mondays-pre-market-session
Olema Pharmaceuticals, Exelixis, Genmab An...
10/20/2025 12:10:45

why-delcath-systems-shares-are-trading-higher-by-over-14-here-are-20-stocks-moving-premarket
Why Delcath Systems Shares Are Trading Hig...
10/20/2025 09:10:06

reported-saturday-exelixis-highlights-81-reduction-in-disease-progression-or-death-with-cabometyx-in-advanced-lung-and-thymic-net-median-progression-free-survival-reached-82-months-vs-27-months-for-placebo
Reported Saturday, Exelixis Highlights 81%...
10/20/2025 08:20:32

– CABOMETYX reduced the risk of disease progression or death by 81% versus placebo in patients with advanced lung or thymic neu...

exelixis-phase-3-stellar-303-zanzalintinib-plus-atezolizumab-extends-survival-to-109-months-in-metastatic-colorectal-cancer
Exelixis Phase 3 STELLAR-303: Zanzalintini...
10/20/2025 06:45:50

– Zanzalintinib in combination with atezolizumab improved median overall survival to 10.9 months versus 9.4 months with regoraf...

morgan-stanley-maintains-overweight-on-exelixis-raises-price-target-to-50
Morgan Stanley Maintains Overweight on Exe...
09/17/2025 18:02:29

Morgan Stanley analyst Sean Laaman maintains Exelixis (NASDAQ:EXEL) with a Overweight and raises the price target from $46 t...

goldman-sachs-initiates-coverage-on-exelixis-with-buy-rating-announces-price-target-of-47
Goldman Sachs Initiates Coverage On Exelix...
09/17/2025 16:38:54

Goldman Sachs analyst Paul Choi initiates coverage on Exelixis (NASDAQ:EXEL) with a Buy rating and announces Price Target of...

17-analysts-have-this-to-say-about-exelixis
17 Analysts Have This To Say About Exelixis
09/17/2025 12:03:18

Core News & Articles
Adagene Expands Announces Amendment Ti 202...
09/16/2025 12:07:09

peering-into-exelixiss-recent-short-interest
Peering Into Exelixis's Recent Short Interest
09/15/2025 20:00:42

is-the-market-bullish-or-bearish-on-exelixis
Is the Market Bullish or Bearish on Exelixis?
08/26/2025 15:01:11

the-analyst-verdict-exelixis-in-the-eyes-of-19-experts
The Analyst Verdict: Exelixis In The Eyes ...
08/12/2025 21:00:59

hc-wainwright--co-maintains-buy-on-exelixis-lowers-price-target-to-46
HC Wainwright & Co. Maintains Buy on Exeli...
08/12/2025 12:10:25

HC Wainwright & Co. analyst Robert Burns maintains Exelixis (NASDAQ:EXEL) with a Buy and lowers the price target from $5...

novo-nordisk-united-parcel-service-and-moderna-are-among-top-10-large-cap-losers-last-week-july-28-august-1-are-the-others-in-your-portfolio
Novo Nordisk, United Parcel Service, And M...
08/03/2025 12:46:33

Ten large-cap stocks, including Novo Nordisk and UPS, tumbled last week on weak earnings and guidance cuts.

ubs-maintains-neutral-on-exelixis-lowers-price-target-to-38
UBS Maintains Neutral on Exelixis, Lowers ...
07/30/2025 15:09:49

UBS analyst Ashwani Verma maintains Exelixis (NASDAQ:EXEL) with a Neutral and lowers the price target from $43 to $38.

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION